Ignite Creation Date:
2024-05-06 @ 3:18 PM
Last Modification Date:
2025-12-17 @ 10:19 AM
Study NCT ID:
NCT04581512
Status:
None
Last Update Posted:
2025-10-14 00:00:00
First Post:
2020-09-16 00:00:00
Brief Title:
Study to Evaluate the Safety and Tolerability of EP0042
Sponsor:
Ellipses Pharma
Organization:
Ellipses Pharma
Study Overview
Official Title:
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Status:
None
Status Verified Date:
2025-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None